NEW YORK, Nov. 17, 2025/ PRNewswire/-- Oramed Pharmaceuticals Inc., a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, today announced its unaudited financial results for the nine months ended September 30, 2025.. Net income of $65.0 million, compared to a net loss of $6.1 million in the same period...

YouTube video by Olivier Niquet

Oramed (Nasdaq: ORMP) reported strategic progress on its oral insulin program, investment gains, and cash growth as of September 30, 2025. The company will run a 60‑patient U.S. trial focused on high‑responder subgroups that showed potential >1% HbA1c reduction. A prior joint venture with Hefei Tianhui Biotech was terminated; Oramed will continue development independently. Oramed described a diversified investment portfolio with material realizations and paper gains (Scilex structured investment returning $95.5M to date with ~ $60M expected in next 12 months; Alpha Tau position valued at ~$64.8M; Pelthos position up ~180%). Cash and assets rose from $155.7M (Jan 2023) to ~$210M (Sep 30, 2025) (unaudited).

YouTube video by Solar Surge

Strategic partnership combines oral drug delivery expertise with alpha-radiation cancer therapy. New funding accelerates US trials and manufacturing. Learn expansion plans.

YouTube video by Bashar Awakening

Oramed Pharmaceuticals (NASDAQ: ORMP) has announced key developments expected for completion in 2025, centered around its new joint venture OraTech Pharmaceuticals. The venture focuses on oral insulin development with planned U.S. Phase 3 trials.Key highlights include:Distribution of majority OraTech holdings to Oramed shareholders via dividend, coinciding with OraTech's planned Nasdaq listingPlanned cash dividend of approximately $0.25 per shareMarketing Authorization Application submitted by HTIT for oral insulin capsule in China, with OraTech expected to receive royaltiesOngoing revenue from Scilex partnership, including $400,000 in royalties due for Q4 2024The company maintains a strong financial position through its Scilex transaction, receiving $70 million from a $99.5 million loan agreement, with additional $53 million expected over two years. Oramed holds 12.25 million Scilex shares, increasing to 18.75 million shares, plus royalty streams from multiple products including ZTlido, ELYXYB, and GLOPERBA.

Oramed launches OraTech Pharmaceuticals with $75M backing, securing manufacturing partnership and advancing oral insulin development with revised Phase 3 trial.

YouTube video by Robyn Adele Anderson

YouTube video by まじめにヤバシティ

YouTube video by Perseus999